Q: Does one dose give the same result as a course?

Not in the animal work, and the direction depends on the animal. In BALB/c mice, Selank in low doses (100 and 300 microg/kg) after single injection reduced the duration of immobility of BALB/c mice in the forced swimming test, a standard mouse test of low mood. The same mice showed no significant effect after repeated injection or after injection in high doses (600 and 900 microg/kg). In rats bred to show low mood, the pattern reversed: Selank in high doses (1000-2000 microg/kg), after repeated injection counteracted symptoms of depression in behavior of WAG/Rij rats. One dose worked in one species and a course worked in another, inside a single paper. That is a warning against reading any one schedule as the way to get a result, and it is a different question from what a person would see.

Q: Why do reported results with Selank vary so much?

The animal work shows at least three reasons, and each one would carry over to people in some form. The first is the amount. In stressed rats, the maximum stress-limiting effect was attained after administration of 300 μg/kg Selank, rather than at the highest amount tested. The second is the starting point. In rats, Selank significantly activated the learning process in rats with initially poor learning ability, and its effect on normal rats peaked later. The third is what else is going on. Under chronic stress, anxiety indicator values after the simultaneous use of diazepam and Selank did not differ from the respective values observed before chronic stress exposure in those rats. Amount, baseline and context all moved the result in rodents. Personal reports add more again: different products, different expectations, and no record of what was in the vial. Wide variation is what this evidence would predict rather than a sign that anyone is lying.

Q: Why might personal reports differ from the trial results?

Because a personal report and a trial result answer different questions, and the Selank trials leave room for both to be partly right. The trials set Selank against a benzodiazepine rather than a dummy, so expectation and the attention of a clinic are part of every patient result. A personal report carries the same effects with no comparison group at all. The material differs too. The researchers who studied its receptor effects describe using HPLC to obtain and ensure reagents and Selank purity, a check most buyers cannot make. And the people differ. The trial patients had diagnosed conditions, such as the 60 patients with phobic-anxiety- and somatoform disorders in the 2014 study. A person without a diagnosis, using unverified material, without a comparison, is in a situation no trial among these sources has measured. That does not make a report false. It means it is not evidence of the same kind.

Question 1

What results have been measured for Selank?

Accepted Answer

In patients, a result means a change on a rating scale, and the trials used a long list of them. The 2015 add-on trial assessed its therapeutic effect clinically and with HDRS, CGI and Spilberger scales, which rate depression, overall illness and anxiety. The same trial added Stroop test and verbal fluency test for thinking, and quality of life was assessed with the SF-36, a general health questionnaire. The 2008 trial used its own set, assessing patients with psychometric scales (Hamilton, Zung, CGI). Outside the patient trials, results were brain-scan readings in healthy people, blood markers, and maze and learning scores in rats and mice. A long list of scales sounds thorough. Without a placebo group, though, each score shows how patients changed over the trial rather than how much of that change belonged to Selank, which is the question a reader most wants answered.

Question 2

How long before Selank results appear?

Accepted Answer

The record gives very different clocks for different measures, from minutes in a scanner to days in a clinic. The fastest human reading came from the brain-scan study, where resting-state fMRI was carried out before, after 5 and 20 min of the injection. In rats, a single injection of selank activated the metabolism of 5-HT in the hypothalamus and caudal brain stem for 30 min to 2 h, 5-HT being serotonin. In mice, the immune gene work found a significant 3-fold decrease in the C3 mRNA level just 30 min after Selank injection. In patients, the closest timing result is that the positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS. A change in a brain chemical within the hour and a faster response on a depression scale are different measures. Neither tells a reader when a person on Selank alone would notice anything.

Question 3

How long do Selank results last?

Accepted Answer

One patient result and one rat result go well beyond the course itself, and both are worth reading closely. In the 2014 patient trial, the anxiolytic effect lasted for a week after last receiving the peptide, anxiolytic meaning anxiety-reducing. In rats trained for a food reward, retention was tested 24 h, 7 and 30 days after treatment. The authors reported that selank induces an increase in memory trace stability during 30 days in those rats. At the level of genes, results faded fast: rat brain tissue showed changes in 45 genes one hour after a dose, and 22 genes changed their expression three hours after it. So a result can fade within hours at the level of genes and still be visible weeks later in behaviour. A week of carry-over in patients is the human figure, and it comes from a trial without a placebo arm, which means some of it may belong to expectation rather than to the peptide.

Question 4

What do before-and-after measurements of Selank show?

Accepted Answer

No personal before-and-after accounts appear in the published record we cite. What exists is a set of measurements taken before and during treatment, mostly of things a person could not feel. In the 2008 trial, enkephalin activity in the blood serum was measured as well, enkephalin being one of the body's own calming signals. As the course went on, that measure rose, and its link with anxiety level grew stronger, mostly in patients with GAD. In the brain-scan study, between-group and between-condition differences were revealed in connectivity between the right amygdala and parts of the right temporal lobe, the amygdala being a brain area tied to fear. These are real before-and-after readings, and the scan one had a placebo group. But a blood marker and a scan show that something changed in the body. They do not show that the person felt better, which is what a before-and-after account usually claims.

Question 5

What did Selank do to quality-of-life scores?

Accepted Answer

Both of the recent patient trials reported a gain, and both measured it in the same way, on a questionnaire. The 2014 trial in 60 patients states that selank had a positive impact on the quality of life of the patients. The 2015 trial tied its gain to two things at once, writing that the therapeutic efficacy and reduction of side-effects had a positive impact on the quality-of-life of the patients treated with selank as add-on to phenazepam. That second sentence matters. Part of the quality-of-life gain came from patients having fewer of phenazepam's side effects, so it is a result about the combination rather than about Selank on its own. Neither summary gives the size of the change. A positive impact on a questionnaire score, without a number and without a placebo group, is a direction rather than an amount.

Question 6

Did Selank show results on thinking tests in patients?

Accepted Answer

The tests were run, but the summaries give little back about them. The 2015 trial lists that Stroop test and verbal fluency test were used, two standard measures of attention and word recall. Its summary then reports anxiety, side-effect and quality-of-life results, and gives no score for either thinking test. The 2014 trial describes the thinking result in words rather than numbers, reporting pronounced anxiolytic and mild nootropic effects of selank. The 2008 trial reports that selank had also antiasthenic and psychostimulant effects, meaning less fatigue and more drive. Mild, in a trial without a placebo arm, is a modest word. The thinking claims made for Selank online lean far more heavily on rat learning experiments than on these patient results, and the patient results do not settle them.

Question 7

What results show up in blood tests?

Accepted Answer

Two patient studies measured blood, one for a calming signal and one for immune messengers. A 2001 study found that Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin, meaning it slowed the breakdown of that calming signal in blood samples taken from patients. The immune study found shifts in the balance of cytokines, the chemical messengers of immune cells, which were found in the serum of patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days. In blood cells grown in a dish, a significant increase (p<0,05) of IL-6 concentration was observed in the cell culture of peripheral blood of patients in the presence of selank, IL-6 being an immune signal. These are measurable results, and they are the kind a laboratory can repeat. What they are not is a symptom result, and none of these studies showed that the blood change and the patient's improvement were the same thing.

Question 8

Does one dose give the same result as a course?

Accepted Answer

Not in the animal work, and the direction depends on the animal. In BALB/c mice, Selank in low doses (100 and 300 microg/kg) after single injection reduced the duration of immobility of BALB/c mice in the forced swimming test, a standard mouse test of low mood. The same mice showed no significant effect after repeated injection or after injection in high doses (600 and 900 microg/kg). In rats bred to show low mood, the pattern reversed: Selank in high doses (1000-2000 microg/kg), after repeated injection counteracted symptoms of depression in behavior of WAG/Rij rats. One dose worked in one species and a course worked in another, inside a single paper. That is a warning against reading any one schedule as the way to get a result, and it is a different question from what a person would see.

Question 9

Why do reported results with Selank vary so much?

Accepted Answer

The animal work shows at least three reasons, and each one would carry over to people in some form. The first is the amount. In stressed rats, the maximum stress-limiting effect was attained after administration of 300 μg/kg Selank, rather than at the highest amount tested. The second is the starting point. In rats, Selank significantly activated the learning process in rats with initially poor learning ability, and its effect on normal rats peaked later. The third is what else is going on. Under chronic stress, anxiety indicator values after the simultaneous use of diazepam and Selank did not differ from the respective values observed before chronic stress exposure in those rats. Amount, baseline and context all moved the result in rodents. Personal reports add more again: different products, different expectations, and no record of what was in the vial. Wide variation is what this evidence would predict rather than a sign that anyone is lying.

Question 10

Why might personal reports differ from the trial results?

Accepted Answer

Because a personal report and a trial result answer different questions, and the Selank trials leave room for both to be partly right. The trials set Selank against a benzodiazepine rather than a dummy, so expectation and the attention of a clinic are part of every patient result. A personal report carries the same effects with no comparison group at all. The material differs too. The researchers who studied its receptor effects describe using HPLC to obtain and ensure reagents and Selank purity, a check most buyers cannot make. And the people differ. The trial patients had diagnosed conditions, such as the 60 patients with phobic-anxiety- and somatoform disorders in the 2014 study. A person without a diagnosis, using unverified material, without a comparison, is in a situation no trial among these sources has measured. That does not make a report false. It means it is not evidence of the same kind.

Question 11

Is Selank worth it?

Accepted Answer

That is a judgement for the reader, and what the evidence can offer is the shape of the case rather than a verdict. On one side are three patient trials that report anxiety relief alongside or comparable to a benzodiazepine, a week of carry-over, and fewer tranquilliser side effects when the two were combined. On the other, none of those trials reports a placebo arm, and the results come from one country's research programme. A 2026 review covering selank among neuroactive peptides sums up the position for the whole group in one line: although preclinical studies are promising, there is a current lack of clinical trials. What is published is mostly about people who were unwell to begin with, such as patients with generalized anxiety disorder (GAD) and neurasthenia. So the record says what was measured in patients under care, and it does not say what a healthy person would get for their money. The two are separate questions, and the research has taken up only the first. What is documented about harm is set out on the Selank safety page.

Selank: reported results by outcome